Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07485829

Zimmer Biomet-RibFix Titan

Prospective, single-center, non-randomized, single-cohort, post-market clinical follow-up study to confirm the safety, performance, and clinical benefits for the use of the RibFix Titan™ system implants and instrumentation) in the fusion, stabilization, and fixation of fractures in the chest wall including rib reconstructive surgical procedures, trauma, or planned osteotomies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ascension St. Vincent Hospital

Indianapolis, Indiana, 46260, United States

Location status: Recruiting

Location contact

Jamie Williams

CONTACT

[email protected]

317-210-3487

Lewis Jacobson, MD

SUB_INVESTIGATOR

Nakul Valsangkar, MD

PRINCIPAL_INVESTIGATOR

About this study

Consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for participation in the study, and will be pre-screened for participation in the informed consent process.

The primary objective is the assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.

This study is designed to evaluate safety parameters by recording the incidence and frequency of complications and adverse events. Relationship of the events to the implant, instrumentation, and/or procedure through the operative and post-operative follow-up periods shall be specified.

The secondary objectives include functional performance and clinical benefits by clinical evaluation of fracture/osteotomy union and patient reported outcome measures (PROMs). This study will also measure resource utilization in subjects with RibFix Titan™, including intensive care unit (ICU) length of stay, hospital length of stay, and operative time.

Data collection will occur at the following intervals: Pre-operative, Operative, 14-days, 45-days, 90-days, and 1-year post-operatively. Enrollment for the study is anticipated to last approximately 12 months. Allowing for 12 months of follow-up, the total estimated study time to final-patient final-visit will be approximately 24 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Willing and able to sign an Institutional Review Board (IRB) approved Informed Consent Form and able to comply with study requirements, in the Investigator's opinion
  • Independent of study participation, patient qualifies for fixation, stabilization, and/or fusion of rib fractures or osteotomies of normal and osteoporotic bone with the study device

Exclusion criteria

  • Midline Sternotomy: sternotomy incisions crossing the midline
  • Active Infection: patients should not have any ongoing infections
  • Material Sensitivity: where sensitivity to materials is suspected, comprehensive testing should be conducted before implantation
  • Inability to Adhere to Post-operative Care: Patients must have the ability and willingness to comply with post-operative care instructions, which may not be possible for individuals with certain mental or neurological conditions
  • Patients not expected to survive the duration of follow-up due to the involvement of trauma situations
  • Patients with a history of alcohol or substance abuse, as well as vulnerable populations such as prisoners and pregnant women

Treatment and study plan

The RibFix Titan™ device should be used within this arm of the study.

Device

Rib Fixation

Primary outcomes

  1. Evaluation of Patient Safety

    Time frame: 90 days

    Assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.

Secondary outcomes

  1. Patient Reported Outcome Measure (PROMIS-Pain Interference 8a)

    Time frame: 12 Months

    8-item questionnaire, completed by the patient, with questions asking the patient to rate how much pain has impacted daily functioning over the past 7 days.

  2. Patient Reported Outcome Measure (PROMIS-Physical Function 10b)

    Time frame: 12 Months

    10-item questionnaire, answered by the patient, with questions asking the patient to rate their level of difficulty performing physical activities.

  3. Patient Reported Outcome Measure (Numeric Pain Rating Scale)

    Time frame: 12 Months

    1-item questionnaire asking the patient to rate their pain on average on a numeric scale, from 0 to 10 where 0 is No Pain and 10 is Worst Imaginable Pain.

Study contacts

Contact information is provided by the study sponsor or research team.

Lynsey Boyle

CONTACT

(412)552-7111

Megan McKinnie

CONTACT

[email protected]

(919)381-7091

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Collaborators

  • Riverpoint Medical

Registry information

Official study title

Zimmer Biomet Patient Outcomes and Experience After Chest Wall Repair With RibFix Titan™

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Mar 20, 2026
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.